Shows
OncotargetOncotarget Sponsors Open Access Team in 2025 Ride for RoswellBUFFALO, NY — June 10, 2025 — The Ride for Roswell, one of the USA’s largest cycling events supporting cancer research, returns to Buffalo on Saturday, June 28, 2025. Hosted annually by Roswell Park Comprehensive Cancer Center, this community-wide event brings together riders, volunteers, and supporters to raise funds for cancer research, celebrate survivors, and honor those lost to the disease.
Among the returning participants is the Open Access Team, led by team captain Sergei Kurenov. This year, the team is once again proudly sponsored by Impact Journals, the publisher of open access journals Oncotarget, Aging, Genes & Cancer, and Oncoscience.
“For the last 10 years, I have con...
2025-06-1002 min
OncotargetOncotarget Participation at SSP 2025 Annual MeetingBUFFALO, NY - May 5, 2025 – Oncotarget, #published by Impact Journals, is proud to #announce its presence as an #exhibitor at the 47th Annual Meeting of the Society for Scholarly Publishing (SSP), taking place May 28–30, 2025, at the Hilton Baltimore in Maryland.
Impact Journals publishes scholarly journals in the biomedical sciences, with a focus on cancer and aging research.
Attendees are invited to stop by Booth #209 to meet members of the Oncotarget team and learn more about the journal’s latest initiatives. This year’s conference theme, “Reimagining the Future of Scholarly Publishing at the Intersection of Value and Values,” highlights critical topics such as arti...
2025-05-0501 min
OncotargetWhen the Cure Becomes the Cause: A Rare Case of Cancer from Donor CellsA young woman beat leukemia; however, nine years later, she faced a different blood cancer. This rare twist, reported recently in Oncotarget, reveals an unexpected risk of bone marrow transplants and opens new questions about long-term outcomes and donor screening.
Bone Marrow Transplant
Bone marrow transplants, also known as hematopoietic stem cell transplants, are often lifesaving for patients with blood cancers like leukemia. These transplants replace a patient’s damaged bone marrow with healthy cells from a donor, giving the body a fresh start. While this treatment can be remarkably effective, it comes with complex risks. Relapse of the original ca...
2025-03-2504 min
OncotargetOncotarget to Participate at the AACR Annual Meeting 2025BUFFALO, NY - March 17, 2025 – Impact Journals (Oncotarget’s publisher), is pleased to announce its participation as an exhibitor at the American Association for Cancer Research (AACR) Annual Meeting 2025. The meeting is scheduled for April 25-30, 2025, at the McCormick Place Convention Center in Chicago, Illinois.
The 2025 AACR Annual Meeting's central theme, "Unifying Cancer Science and Medicine: A Continuum of Innovation for Impact," highlights major breakthroughs and innovative developments transforming cancer research. Oncotarget aligns directly with this vision, being always committed to rapidly publishing and disseminating impactful research findings across diverse areas of cancer science and thus advancing cancer treatment and patient care...
2025-03-1202 min
OncotargetA New Path to Tumor Suppression: The Promise of PG3The p53 protein, often called the “guardian of the genome,” is crucial for preventing cancer by repairing damaged DNA or triggering cell death in cells that cannot be repaired. However, in about half of all cancers, the p53 gene is mutated, making the protein ineffective. A groundbreaking study has introduced PG3, a new compound that restores tumor suppression without relying on p53, offering a new option to treat resistant cancers.
Published in Oncotarget on September 17, 2024, the study titled “Integrated stress response (ISR) activation and apoptosis through HRI kinase by PG3 and other p53 pathway-restoring cancer therapeutics,” introduces PG3, a small molecule...
2024-12-1806 min
OncotargetOncotarget Welcomes New Editorial Board MembersBUFFALO, NY - July 22, 2024 – Oncotarget proudly welcomes new members to our esteemed Editorial Board, including our new Co-Editor-in-Chief, Dr. Wafik S. El-Deiry.
Joining Dr. El-Deiry on Oncotarget’s Editorial Board are Dr. Trever Bivona, Dr. Phillip Buckhaults, Dr. Fred Bunz, Dr. Jonathan Chernoff, Dr. Stephen G. Chun, Dr. Nathan Dolloff, Dr. Peiwen Fei, Dr. Justin D. Lathia, Dr. Bora Lim, Dr. Jia (Jenny) Liu, Dr. Hui-Wen Lo, Dr. Emil Lou, Dr. Anirban Maitra, Dr. Ruben A. Mesa, and Dr. Yashbir Singh.
To learn more about our outstanding members, please visit our Editorial Board page.
In celebration of the new additions to O...
2024-07-2201 min
OncotargetAI for Improved PET/CT Attenuation Correction in Prostate Cancer ImagingPositron Emission Tomography (PET) combined with Computed Tomography (CT) is a powerful imaging modality used in oncology for diagnosis, staging, and treatment monitoring. However, one limitation of PET/CT is the need for accurate attenuation correction (AC) to account for tissue density variations. Traditionally, low-dose CT scans are used for AC, but these contribute to patient radiation exposure.
In a new study, researchers Kevin C. Ma, Esther Mena, Liza Lindenberg, Nathan S. Lay, Phillip Eclarinal, Deborah E. Citrin, Peter A. Pinto, Bradford J. Wood, William L. Dahut, James L. Gulley, Ravi A. Madan, Peter L. Choyke, Ismail Baris Turkbey, and...
2024-07-1105 minOncotargetOncotarget at SSP 46th Annual MeetingBUFFALO, NY- May 13, 2024 – BUFFALO, NY- May 13, 2024 – Impact Journals publishes scholarly journals in the biomedical sciences, with a focus on all areas of cancer and aging research. Oncotarget is one of the most prominent journals published by Impact Journals.
Impact Journals is proud to participate at the Society for Scholarly Publishing (SSP) 46th Annual Meeting, which convenes in Boston, Massachusetts, at the Westin Boston Seaport District from May 29–31, 2024. This year, the SSP Annual Meeting theme is “Inflection Point: Setting the Course for the Future of Scholarly Communication.”
Visit booth #212 at the SSP 46th Annual Meeting 2024 to connect with members of the Oncotarget...
2024-05-1301 minOncotargetOncotarget Sponsors 19th International p53 Workshop in ItalyBUFFALO, NY- April 29, 2024 – Oncotarget is a contributing #sponsor at the 19th International p53 Workshop, organized by the International Center for Genetic Engineering and Biotechnology (ICGEB), which takes place from May 13–16, 2024, in Trieste, Italy.
“Groundbreaking research and cutting-edge advancements in the field of the most studied human gene and most frequently mutated gene in cancer, will take center stage at the 19th International p53 Workshop.” – ICGEB.org
Among the 24 invited speakers at the 19th International p53 Workshop, 18 speakers have published new research on p53 in Oncotarget. These distinguished speakers who have published with Oncotarget include Dr. Andrei Gudkov — one of Oncotarget’s founding Edi...
2024-04-2902 minOncotargetOncotarget at AACR Annual Meeting 2024BUFFALO, NY- March 11, 2024 – Impact Journals publishes #scholarly journals in the #biomedical sciences with a focus on all areas of cancer and aging research. Oncotarget is one of the most prominent journals published by Impact Journals.
Impact Journals will be participating as an exhibitor at the American Association for Cancer Research (AACR) Annual Meeting 2024 from April 5-10 at the San Diego Convention Center in San Diego, California. This year, the AACR meeting theme is “Inspiring Science • Fueling Progress • Revolutionizing Care.”
Visit booth number 4159 at the AACR Annual Meeting 2024 to connect with members of the Oncotarget team.
About Oncotarget:
Oncotarget (a primarily oncology-f...
2024-03-1101 min
OncotargetOncotarget’s Top 10 Papers Published in 2023 (Crossref Data)Crossref is a non-profit organization that logs and updates citations for scientific publications. Each month, Crossref identifies a list of the most popular Oncotarget papers based on the number of times a DOI is successfully resolved.
Below are Crossref’s Top 10 Oncotarget DOIs published in 2023.
10: Everolimus downregulates STAT3/HIF-1α/VEGF pathway to inhibit angiogenesis and lymphangiogenesis in TP53 mutant head and neck squamous cell carcinoma (HNSCC)
DOI: https://doi.org/10.18632/oncotarget.28355
Authors: Md Maksudul Alam, Janmaris Marin Fermin, Mark Knackstedt, Mackenzie J. Noonan, Taylor Powell, Landon Goodreau, Emily K. Daniel, Xiaohua Rong, Tara Moore-Medlin, Alok R. Khandelwal, and Cherie-Ann O. Nat...
2024-02-1505 min
OncotargetHER3: A Vital Target in Cancer TreatmentDr. Omkar Desai, from the Department of Surgery at Case Western Reserve University and University Hospitals Cleveland Medical Center, describes a research perspective he co-authored with Dr. Rui Wang that was published by Oncotarget in Volume 14, entitled, “HER3- A key survival pathway and an emerging therapeutic target in metastatic colorectal cancer and pancreatic ductal adenocarcinoma.”
DOI - https://doi.org/10.18632/oncotarget.28421
Correspondence to - Rui Wang - rxw517@case.edu
Author video - https://www.youtube.com/watch?v=3-02jt7-MW8
Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=1...
2023-10-1208 min
OncotargetTurning Immunosuppressive Tumors to Immunostimulatory: Nerofe and Doxorubicin's ImpactA new research paper was published in Oncotarget's Volume 14 on July 1, 2023, entitled, “Transformation of immunosuppressive mtKRAS tumors into immunostimulatory tumors by Nerofe and Doxorubicin.”
Members of the rat sarcoma viral oncogene (RAS) subfamily KRAS are frequently mutated oncogenes in human cancers and have been identified in pancreatic ductal, colorectal, and lung adenocarcinomas. Recently, two drugs that specifically target KRAS G12C, sotorasib (Lumakras™) and adagrasib (Krazati™), have received accelerated approval by the FDA for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic NSCLC, who have received at least one prior systemic therapy. These drugs are the firs...
2023-07-0603 min
OncotargetERβ as a Mediator of Estrogen Signaling in Inflammatory Breast CancerA new editorial paper was published in Oncotarget's Volume 14 on June 12, 2023, entitled, “ERβ as a mediator of estrogen signaling in inflammatory breast cancer.”
In this new editorial, researchers Harika Nagandla and Christoforos Thomas from Houston Methodist Neal Cancer Center discuss inflammatory breast cancer (IBC)—a rare and aggressive form of breast cancer which accounts for 2–4% of all new breast cancer cases detected in the United States. Even with the application of standard multi-modality treatment approach that incorporates neoadjuvant chemotherapy, radiation and surgery, the 5-year survival rate for IBC is only about 40–50%. Breast cancer can be typically stratified into different types based on th...
2023-07-0303 min
OncotargetNovel GEM Model Unveils PLK1’s Role in TumorigenesisOn the bright side, polo-like kinase 1 (PLK1) is considered a master regulator of the ever-important cell cycle. On the dark side, PLK1 expression (at both the mRNA and protein level) has shown to be upregulated in tumor cells, suggesting that PLK1 may also contribute to tumorigenesis. Despite this direct association, researchers studying the role of PLK1 in cancer have encountered a problem: a lack of appropriate animal models for experimentation.
“Even though studies have suggested that PLK1 contributes to tumorigenesis, the ability of PLK1 to drive oncogenic transformation on its own in vivo was still questionable due to a lack of...
2023-06-3005 min
OncotargetDecoding the Mechanism Behind MCL-1 Inhibitors: A Pathway to Understanding MCL-1 Protein StabilityA new editorial paper was published in Oncotarget's Volume 14 on June 21, 2023, entitled, “Decoding the mechanism behind MCL-1 inhibitors: A pathway to understanding MCL-1 protein stability.”
The successful development of the BCL-2 inhibitor venetoclax, currently approved for chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML), encouraged the development of inhibitors that target other antiapoptotic proteins, particularly Myeloid Leukemia 1 (MCL-1). MCL-1 is among the top genes amplified in several cancers and is implicated in cancer progression, drug resistance and poor prognosis. It protects cancer cells from apoptosis and decreases their sensitivity to targeted agents or chemotherapeutics.
In this new editorial, researchers Shad...
2023-06-2802 min
OncotargetDPDT Anticancer Activity in Human Colon Cancer HCT116 CellsA new research paper was published in Oncotarget's Volume 14 on June 21, 2023, entitled, “Diphenyl ditelluride anticancer activity and DNA topoisomerase I poisoning in human colon cancer HCT116 cells.”
Diphenyl ditelluride (DPDT) is an organotellurium (OT) compound with pharmacological properties, including antioxidant, antigenotoxic and antimutagenic activities when applied at low concentrations. However, DPDT as well as other OT compounds also show cytotoxicity against mammalian cells when treatments occur at higher drug concentrations. The underlying mechanisms of toxicity of DPDT against tumor cells have previously been poorly explored.
In this new study, researchers André Luiz Mendes Juchem, Cristiano Trindade, Juliana Bondan da Silva, Miria...
2023-06-2603 minOncotargetTargeting GITR in Cancer Immunotherapy – There Is No Perfect KnowledgeA new research perspective was published in Oncotarget's Volume 14 on June 19, 2023, entitled, “Targeting GITR in cancer immunotherapy – there is no perfect knowledge.”
In this new perspective, researchers Diwakar Davar and Roberta Zappasodi from the University of Pittsburgh Medical Center (UPMC), University of Pittsburgh, Weill Cornell Medical College, and Weill Cornell Graduate School of Medical Sciences discuss the glucocorticoid-induced TNFR-related protein (GITR), belonging to the TNFR superfamily (TNFRSF) and stimulating both the acquired and innate immunity. GITR is broadly expressed on immune cells, particularly regulatory T cells (Tregs) and natural killer (NK) cells.
“Given its potential to promote T effector function and impe...
2023-06-2103 min
OncotargetMetformin's Role in Preventing Metabolic Syndrome During Androgen Deprivation TherapyA new research paper was published in Oncotarget's Volume 14 on June 19, 2023, entitled, “Utilizing metformin to prevent metabolic syndrome due to androgen deprivation therapy (ADT): a randomized phase II study of metformin in non-diabetic men initiating ADT for advanced prostate cancer.”
Androgen deprivation therapy (ADT) can lead to metabolic syndrome (MS) and is implicated in ADT-resistance. Metformin showed antineoplastic activity through mTOR inhibition secondary AMPK-activation.
To investigate whether metformin mitigated ADT-related MS, researchers Devalingam Mahalingam, Salih Hanni, Anthony V. Serritella, Christos Fountzilas, Joel Michalek, Brian Hernandez, John Sarantopoulos, Paromitta Datta, Ofelia Romero, Sureshkumar Mulampurath Achutan Pillai, John Kuhn, Michael Pollak6, and Ian...
2023-06-2003 min
OncotargetOncotarget Sponsors 2023 Ride for RoswellThe Ride for Roswell is one of the nation’s largest cycling events—hosted by Roswell Park Comprehensive Cancer Center—to raise awareness and funds for cancer research and patient care. This charity bike ride, based out of Buffalo, New York, has brought people together for 27 years to celebrate cancer survivors, pay tribute to lives that have been lost, and to work together to support research and find a cure.
When its doors opened in Buffalo in 1898, Roswell Park Comprehensive Cancer Center was the first cancer research-focused institution in the world. Today, this institution is one of only four National Cancer...
2023-06-1905 min
OncotargetACSL4: Biomarker, Mediator and Target in Quadruple Negative Breast CancerA new review paper was published in Oncotarget's Volume 14 on June 12, 2023, entitled, “ACSL4: biomarker, mediator and target in quadruple negative breast cancer.”
Breast cancer is a heterogeneous disease for which effective treatment depends on correct categorization of its molecular subtype. For the last several decades this determination has relied on hormone receptor status for estrogen, progesterone and HER2. More recently, gene expression data have been generated that further stratify both receptor-positive and receptor-negative cancers.
In this new review, researcher Marie E. Monaco from NYU Grossman School of Medicine and VA NY Harbor Healthcare System discusses the fatty acid-activating enzyme, ACSL4, whic...
2023-06-1403 min
OncotargetLP-284 Targets Non-Hodgkin's Lymphoma and DNA Damage Repair DeficiencyA new research paper was published in Oncotarget's Volume 14 on June 12, 2023, entitled, “LP-284, a small molecule acylfulvene, exerts potent antitumor activity in preclinical non-Hodgkin's lymphoma models and in cells deficient in DNA damage repair.”
Despite advances in therapies treating non-Hodgkin’s lymphoma (NHL), 20~40% of patients experience relapsed or refractory disease. While solid tumors with homologous recombination deficiencies have been successfully targeted with synthetic lethal agents such as poly-ADP ribose polymerase (PARP) inhibitors, such synthetic lethality strategy has not yet been approved to treat patients with NHL.
In this new study, researchers Jianli Zhou, Drew Sturtevant, Cassie Love, Aditya Kulkarni, Neha Biyani...
2023-06-1203 min
OncotargetTargeting the Src N-Terminal Regulatory Element in CancerA new research perspective was published in Oncotarget's Volume 14 on May 19, 2023, entitled, “Targeting the Src N-terminal regulatory element in cancer.”
The signaling pathways displayed by cancer cells are often composed of the same components as the physiological ones, yet the overall result is a pathological deregulation. In this new paper, researchers Betlem Mezquita, Marjorie Reyes-Farias and Miquel Pons from the Universitat de Barcelona and Universitat Internacional de Catalunya discuss the non-receptor protein tyrosine kinase Src as a good example.
“Src, the first discovered oncogene, is the leading member of the Src family of kinases (SFK) that includes Fyn, Yes, Blk, Yrk, F...
2023-06-0903 min
OncotargetValue of Chemotherapy Post Immunotherapy in Stage IV Non-Small Cell Lung CancerA new research paper was published in Oncotarget's Volume 14 on May 26, 2023, entitled, “Value of chemotherapy post immunotherapy in stage IV non-small cell lung cancer (NSCLC).”
Lung cancer is the number one cause of mortality among all types of cancer worldwide. Its treatment landscape has shifted from the classic chemotherapy alone to newer regimens based on the discovery of new immunotherapy and targeted therapy drugs. However, chemotherapy is still an option for treatment of advanced non-small cell lung cancer (NSCLC) after progression on immunotherapy alone or in combination with first-line chemotherapy.
This new retrospective study, by researchers Hazem I. Assi, Maroun Bou...
2023-06-0703 min
OncotargetBORIS Gene Mutation and Expression: Link to Breast Cancer ProgressionA new research paper was published in Oncotarget's Volume 14 on May 26, 2023, entitled, “Association of mutation and expression of the brother of the regulator of imprinted sites (BORIS) gene with breast cancer progression.”
The brother of the regulator of imprinted sites (BORIS), 11 zinc-finger transcription factors, is a member of the cancer-testis antigen (CTA) family. It is mapped to chromosome number 20q13.2 and this region is genetically linked to the early onset of breast cancer.
In the current study, researchers Mohammad Salman Akhtar, Naseem Akhter, Arshi Talat, Raed A. Alharbi, Abdulmajeed A.A. Sindi, Faisal Klufah, Hanan E. Alyahyawi, Abdulmohsen Alruwetei, Abrar Ahma...
2023-06-0603 min
OncotargetDeconstructing the Role of MALAT1 in MAPK-Signaling in MelanomaA new research paper was published in Oncotarget's Volume 14 on May 26, 2023, entitled, “Deconstructing the role of MALAT1 in MAPK-signaling in melanoma: insights from antisense oligonucleotide treatment.”
The long non-coding RNA (lncRNA) MALAT1 is a regulator of oncogenesis and cancer progression. MAPK-pathway upregulation is the main event in the development and progression of human cancer, including melanoma and recent studies have shown that MALAT1 has a significant impact on the regulation of gene and protein expression in the MAPK pathway. However, the role of MALAT1 in regulation of gene and protein expression of the MAPK-pathway kinases RAS, RAF, MEK, and ERK in m...
2023-05-3003 min
OncotargetCan the Creatine Shuttle be Targeted to Fight Colorectal Cancer?Blog summary: “Role of creatine shuttle in colorectal cancer cells.”
_____________________________________________
Since the 1992 Barcelona Olympics, creatine supplementation has increased in popularity and grown to widespread use among the mainstream public. Creatine is a naturally occurring compound, primarily stored in skeletal muscle and involved in energy production for high-intensity activities—enhancing performance and supporting muscle growth and strength. The process by which creatine is transported into the muscles and utilized for energy production is referred to as the creatine shuttle. While it is a useful mechanism for healthy muscles, the creatine shuttle has also been implicated in cancer.
“The creatine shuttle is highligh...
2023-05-2606 min
OncotargetBehind the Study: Molecular Dialogue Between Tumor Cells and FibroblastsDr. Gopal C. Kundu from KIIT Deemed to be University in Odisha, India, describes a recent editorial he co-authored that was published by Oncotarget in Volume 14, entitled, “The molecular dialogue between the tumor cells and fibroblasts.”
DOI - https://doi.org/10.18632/oncotarget.28405
Correspondence to - Gopal C. Kundu - gopalc.kundu@kiit.ac.in
Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28405
Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/
Keywords - CAFs, heterogeneity, myofibroblasts, drug resistance, osteopontin
About Oncotarget
Oncotarget is a primarily onco...
2023-05-2406 minOncotargetHER3: Survival Pathway and Therapeutic Target in Metastatic Colorectal and Pancreatic CancerA new research perspective was published in Oncotarget's Volume 14 on May 10, 2023, entitled, “HER3- A key survival pathway and an emerging therapeutic target in metastatic colorectal cancer and pancreatic ductal adenocarcinoma.”
Colorectal cancer (CRC) and pancreatic ductal adenocarcinoma (PDAC) are highly metastatic cancers with poor survival rates. The tumor microenvironment has been shown to play a critical role in cancer progression and response to therapies. Endothelial cells (ECs) are a key component of the tumor microenvironment and promote cancer cell survival by secreting soluble factors that activate cancer-promoting signaling pathways.
In this new perspective, researchers Omkar Desai and Rui Wang from...
2023-05-2403 min
OncotargetGPR141 Regulates Breast Cancer Progression via Oncogenic Mediators and the p-mTOR/p53 AxisA new research paper was published in Oncotarget's Volume 14 on May 19, 2023, entitled, “G-protein-coupled receptor 141 mediates breast cancer proliferation and metastasis by regulating oncogenic mediators and the p-mTOR/p53 axis.”
Breast cancer morbidity is surging towards the peak in females across the globe. An inherent property of cancer cells is enhanced cell proliferation rate and migration capability, leading to deregulated cell signaling cascades. G-protein-coupled receptors (GPCRs) have recently emerged as a hot-spot target in cancer research.
Researchers Monalisa Parija, Amit K. Adhya and Sandip K. Mishra from the Institute of Life Sciences, Regional Centre for Biotechnology and All India Institute of Medi...
2023-05-2203 min
OncotargetTargeting Cellular Respiration as a Therapeutic Strategy in GlioblastomaA new research perspective was published in Oncotarget's Volume 14 on May 4, 2023, entitled, “Targeting cellular respiration as a therapeutic strategy in glioblastoma.”
While glycolysis is abundant in malignancies, mitochondrial metabolism is significant as well. Mitochondria harbor the enzymes relevant for cellular respiration, which is a critical pathway for both regeneration of reduction equivalents and energy production in the form of ATP.
In this research perspective, researchers Enyuan Shang, Trang Thi Thu Nguyen, Mike-Andrew Westhoff, Georg Karpel-Massler, and Markus D. Siegelin from Columbia University Medical Center, City University of New York and Ulm University Medical Center discuss their recent finding that FDA-approved HDAC...
2023-05-1903 min
OncotargetImpact Journals (Oncotarget's Publisher) at SSP 45th Annual MeetingImpact Journals (Oncotarget's publisher) will be participating as an exhibitor at the Society for Scholarly Publishing (SSP) 45th Annual Meeting, which convenes on May 31–June 2, 2023, at the Oregon Convention Center & Hyatt Regency Portland in Portland, Oregon, USA. This year, the SSP’s meeting theme is: “Transformation, Trust, and Transparency.”
“The pace of change in our industry continues unabated, with seismic shifts in areas such as the dissemination of research, business models, and the nature of the workplace. And yet, while pressure for change has become the new normal, fundamental change has proved more elusive. We invite you to join us in highlig...
2023-05-1701 minOncotargetAutomated, Accurate Reporting for NGS-Based Clonality TestingA new research paper was published in Oncotarget's Volume 14 on May 12, 2023, entitled, “Development and implementation of an automated and highly accurate reporting process for NGS-based clonality testing.”
B and T cells undergo random recombination of the VH/DH/JH portions of the immunoglobulin loci (B cell) and T-cell receptors before becoming functional cells. When one V-J rearrangement is over-represented in a population of B or T cells indicating an origin from a single cell, this indicates a clonal process. Clonality aids in the diagnosis and monitoring of lymphoproliferative disorders and evaluation of disease recurrence.
In a new study, researchers Sean T. G...
2023-05-1602 min
OncotargetReaching the Brain Through the Groin: A Novel Approach to Brain CancerBlog summary: “From the groin to the brain: a transfemoral path to blood-brain barrier opening.”
___________________________________________
Just a small number of molecules, including alcohol and caffeine, are able to cross the blood-brain barrier (BBB). The BBB is a highly selective semipermeable membrane that separates circulating blood from extracellular fluid in the brain. It plays a critical role in protecting the brain from harmful substances in the blood while also maintaining a stable and consistent environment for neuronal function. Without the BBB, humans would be at the mercy of any harmful toxin, pathogen and unwanted substance that could cross from the bloodstream into...
2023-05-1208 min
OncotargetUsing Cancer Proteomics Data to Identify Gene Candidates for Therapeutic TargetingA new research perspective was published in Oncotarget's Volume 14 on May 4, 2023, entitled, “Using cancer proteomics data to identify gene candidates for therapeutic targeting.”
Gene-level associations obtained from mass-spectrometry-based cancer proteomics datasets represent a resource for identifying gene candidates for functional studies. In their new research perspective, researchers Diana Monsivais, Sydney E. Parks, Darshan S. Chandrashekar, Sooryanarayana Varambally, and Chad J. Creighton from Baylor College of Medicine and University of Alabama at Birmingham discuss their recent study where they surveyed proteomic correlates of tumor grade across multiple cancer types and identified specific protein kinases having a functional impact on uterine endometrial canc...
2023-05-1002 min
OncotargetDefining the Complexity of EGFR Endocytosis in CancerListen to a blog summary of an editorial perspective that was published in Oncotarget’s Volume 14, entitled, “EGFR endocytosis: more than meets the eye.”
_________________________________
EGFR (epidermal growth factor receptor) is a crucial protein that plays a significant role in various biological processes such as cell growth, proliferation, differentiation, and survival. Dysregulation of EGFR signaling has been implicated in the development and progression of numerous human cancers, including lung, breast and colon cancer. Therefore, EGFR has emerged as an attractive target for cancer therapy, and several drugs that target EGFR are in clinical use or under investigation.
In recent years, endocytosis, the pr...
2023-04-2807 min
OncotargetThe Evolution of Metastatic Cancer: Mechanisms and DriversListen to a blog summary of an editorial published in Oncotarget on March 21, 2023, entitled, “Therapy drives genomic evolution in metastatic cancer.
_________________________________________________
There are several theories that attempt to explain the genesis of cancer. One prominent theory is the genetic theory—proposing that cancer may arise from the accumulation of genetic mutations that alter the normal functioning of cells. These mutations can drive the formation of tumors, which can then spread to other parts of the body in a process known as metastasis. Metastatic cancer is often difficult to treat because it has evolved to become resistant to standard therapies.
“It is gen...
2023-04-1707 minOncotargetOncotarget at AACR Annual Meeting 2023Impact Journals (Oncotarget's publisher) will be participating as an exhibitor at the American Association for Cancer Research (AACR) Annual Meeting 2023 from April 14-19 at the Orange County Convention Center in Orlando, Florida. This year, the AACR meeting theme is: “Advancing the Frontiers of Cancer Science and Medicine.”
Impact Journals publishes scholarly journals in the biomedical sciences with a focus on all areas of cancer and aging research. Oncotarget is one of the most prominent journals published by Impact Journals. Oncotarget is indexed/archived on MEDLINE, PMC and PubMed.
Visit booth No. 2642 at the AACR Annual Meeting 2023 to connect with members of t...
2023-04-0701 min
OncotargetUnconventional Protein Secretion (UPS) in CancerBlog summary of an editorial perspective published in Oncotarget on entitled, “Leakage? or Secretion? unconventional protein secretion in cancer.”
________________________________________
Conventional protein secretion is fairly well understood in this day and age. Proteins that are secreted through the classical, secretory vesicle-related pathway contain a signal peptide that guides them to the endoplasmic reticulum (ER), where they are further processed and transported to the Golgi apparatus. From there, the Golgi apparatus modifies, sorts and packages proteins for transport to their final destinations within the cell or for secretion outside of the cell.
However, in recent years, it has become clear that not all...
2023-03-1706 min
OncotargetOncotarget’s Top 10 Papers In 2022 (Crossref Data)Crossref is a non-profit organization that logs and updates citations for scientific publications. Each month, Crossref identifies a list of the most popular Oncotarget papers based on the number of times a DOI is successfully resolved. Below are Crossref’s Top 10 Oncotarget DOIs in 2022.
10: Cell fusion as a link between the SARS-CoV-2 spike protein, COVID-19 complications, and vaccine side effects
DOI: https://doi.org/10.18632/oncotarget.28088
Author: Yuri Lazebnik
9: A Jurkat 76 based triple parameter reporter system to evaluate TCR functions and adoptive T cell strategies
DOI: https://doi.org/10.18632/oncotarget.24807
Authors: Sandra Rosskopf, Judith Leitner, Wolfgang Paster, Laura T. Morton, Renate S...
2023-02-2108 minOncotargetPress Release: Oncotarget Is Again On MEDLINEBUFFALO, NY- October 27, 2022 – On September 15, 2022, Oncotarget was accepted again for indexing by MEDLINE. Oncotarget is now indexed by MEDLINE/PubMed and PubMed Central/PubMed.
***
The United States government is firmly committed to making credible biomedical research available to the public. In operation since 1996, PubMed is an online biomedical literature database operated by the U.S. National Institutes of Health (NIH). PubMed provides free access to over 34 million citations from MEDLINE, PubMed Central (PMC) and the National Center for Biotechnology Information databases.
Started back in the 1960s, MEDLINE is a large bibliographic citation and abstract database for life science articles in jo...
2022-10-2702 min
OncotargetOncotarget’s Top-10 Most-Viewed Papers in 2021Listen to a list of the 10 most-viewed oncology-focussed papers on Oncotarget.com in 2021.
10 - “Metformin and berberine, two versatile drugs in treatment of common metabolic diseases”
DOI - https://doi.org/10.18632/oncotarget.20807
9 - “Cell fusion as a link between the SARS-CoV-2 spike protein, COVID-19 complications, and vaccine side effects”
https://doi.org/10.18632/oncotarget.28088
8 - “Physical activity and telomere length: Impact of aging and potential mechanisms of action”
https://doi.org/10.18632/oncotarget.16726
7 - “Hedgehog signaling induces PD-L1 expression and tumor cell proliferation in gastric cancer”
https://doi.org/10.18632/oncotarget.26473
6 - “cGAS-STING pathway in oncogenesis and cancer therapeutics”
https://doi.org/10.18632/oncotarget.27673
5 - “Anti-aging: senolytic...
2022-01-2107 min
OncotargetAnnouncement: Open-Access Oncotarget Shifts to Continuous PublishingBUFFALO, NY, January 6, 2022 – Since its inception in 2010, Oncotarget has operated as a traditional-style journal that publishes online page numbered issues of peer-reviewed papers. Final paginated issues were then released in their permanent form to Pubmed.
As of 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form. This means that qualified, rigorously peer-reviewed articles will be published online as soon as they are in their fully formatted and final version of record. With continuous publication, articles posted online are complete with citation details and are available in fu...
2022-01-0602 min
OncotargetTable of Contents: Volume 12, Issue #24Listen to short summaries of the latest oncology-focused research published in this week’s issue of Oncotarget, Volume 12, Issue 24.
https://www.oncotarget.com/archive/v12/i24/
Research Paper (Cover) - “CCL20 induces colorectal cancer neoplastic epithelial cell proliferation, migration, and further CCL20 production through autocrine HGF-c-Met and MSP-MSPR signaling pathways”
https://doi.org/10.18632/oncotarget.28131
Research Paper - “The potential of PIVKA-II as a treatment response biomarker in hepatocellular carcinoma: a prospective United Kingdom cohort study”
https://doi.org/10.18632/oncotarget.28136
Research Paper - “Caloric restriction causes a distinct reorganization of the lipidome in quiescent and non-quiescent cells of budding yeast”
https://doi.org/10.186...
2021-11-2307 min
OncotargetTable of Contents: Volume 12, Issue #22Listen to the latest oncology-focused research published in this week’s issue of Oncotarget, Volume 12, Issue 22.
https://www.oncotarget.com/archive/v12/i22/
Research Paper (Cover) - “P10s-PADRE vaccine combined with neoadjuvant chemotherapy in ER-positive breast cancer patients induces humoral and cellular immune responses”
https://doi.org/10.18632/oncotarget.28083
Research Paper - “Dishevelled-1 DIX and PDZ domain lysine residues regulate oncogenic Wnt signaling”
https://doi.org/10.18632/oncotarget.28089
Research Paper - “THSB2 as a prognostic biomarker for patients diagnosed with metastatic pancreatic ductal adenocarcinoma”
https://doi.org/10.18632/oncotarget.28099
Research Paper - “Comparison of MET gene amplification analysis by next-generation sequencing and fluorescence in...
2021-10-2806 min
OncotargetTable of Contents: Volume 12, Issue #21Listen to the latest oncology-focused research published in this week’s issue of Oncotarget, Volume 12, Issue 21.
https://www.oncotarget.com/archive/v12/i21/
Priority Research Paper (Cover) - “ATR inhibition reverses the resistance of homologous recombination deficient MGMTlow/MMRproficient cancer cells to temozolomide”
https://doi.org/10.18632/oncotarget.28090
Research Paper - “Hyperprogression of a mismatch repair-deficient colon cancer in a humanized mouse model following administration of immune checkpoint inhibitor pembrolizumab”
https://doi.org/10.18632/oncotarget.28086
Research Paper - “Luminescence complementation technology for the identification of MYC:TRRAP inhibitors”
https://doi.org/10.18632/oncotarget.28078
Research Paper - “TAK1-inhibitors are cytotoxic for multiple myeloma cells alone and...
2021-10-1308 min
OncotargetTable of Contents: Volume 12, Issue #20Listen to summaries of the latest oncology-focused research published in this week’s issue of Oncotarget, Volume 12, Issue 20.
https://www.oncotarget.com/archive/v12/i20/
Priority Research Paper (Cover) - “Identification of Smurf2 as a HIF-1α degrading E3 ubiquitin ligase”
https://doi.org/10.18632/oncotarget.28081
Research Paper - “A high-throughput customized cytokinome screen of colon cancer cell responses to small-molecule oncology drugs”
https://doi.org/10.18632/oncotarget.28079
Research Paper - “Opposing effects of BRCA1 mRNA expression on patient survival in breast and colorectal cancer and variations among African American, Asian, and younger patients”
https://doi.org/10.18632/oncotarget.28082
Research Paper - “Pan-drug and drug-specific mec...
2021-09-2911 min
OncotargetTable of Contents: Volume 12, Issue #19Listen to summaries of the latest oncology-focused research published in this week’s issue of Oncotarget, Volume 12, Issue 19.
https://www.oncotarget.com/archive/v12/i19/
Cover Paper - “Nanoparticle T cell engagers for the treatment of acute myeloid leukemia”
https://doi.org/10.18632/oncotarget.28054
News - “Old drug, new trick: proton pump inhibitors find new purpose in cancer care”
https://doi.org/10.18632/oncotarget.28053 (PDF Download)
Research Paper - “Novel insights into the molecular mechanisms underlying risk of colorectal cancer from smoking and red/processed meat carcinogens by modeling exposure in normal colon organoids”
https://doi.org/10.18632/oncotarget.28058
Research Paper - “Altered glucuronidation...
2021-09-1511 min
OncotargetTable of Contents: Volume 12, Issue #18Listen to the latest oncology-focused research published in this week’s issue of Oncotarget, Volume 12, Issue 18.
https://www.oncotarget.com/archive/v12/i18/
Priority Research Paper (Cover) - “Normal tissue and tumor microenvironment adaptations to aerobic exercise enhance doxorubicin anti-tumor efficacy and ameliorate its cardiotoxicity in retired breeder mice”
https://doi.org/10.18632/oncotarget.28057
Research Paper - “Selinexor, a selective inhibitor of nuclear export, enhances the anti-tumor activity of olaparib in triple negative breast cancer regardless of BRCA1 mutation status”
https://doi.org/10.18632/oncotarget.28047
Research Paper - “Pim kinase inhibitor co-treatment decreases alternative non-homologous end-joining DNA repair and genomic instability induced by topoisome...
2021-09-0109 min
OncotargetTable Of Contents: Volume 12, Issue #17Listen to the latest oncology-focused research published in this week’s issue of Oncotarget, Volume 12, Issue 17.
https://www.oncotarget.com/archive/v12/i17/
Research Paper (Cover) - “Scent test using Caenorhabditis elegans to screen for early-stage pancreatic cancer”
https://doi.org/10.18632/oncotarget.28035
Research Paper - “The role of circulating miRNAs and CA19-9 in pancreatic cancer diagnosis”
https://doi.org/10.18632/oncotarget.28038
Research Paper - “Diverse transcriptional regulation and functional effects revealed by CRISPR/Cas9-directed epigenetic editing”
https://doi.org/10.18632/oncotarget.28037
Research Paper - “The protective role of Prolyl oligopeptidase (POP) inhibition in acute lung injury induced by intestinal ischemia-reperfusion” https://doi.org/10...
2021-08-1807 min
OncotargetTable of Contents: Oncotarget Volume 12, Issue #16Listen to the latest oncology-focused research published in this week’s issue of Oncotarget, Volume 12, Issue 16.
https://www.oncotarget.com/archive/v12/i16/
Cover Paper - “Epigenetic signatures differentiate uterine and soft tissue leiomyosarcoma”
https://doi.org/10.18632/oncotarget.28032
Research Paper - “High CD39 expression is associated with the non-muscle-invasive phenotype of human bladder cancer” https://doi.org/10.18632/oncotarget.28029
Research Paper - “MiR-7-5p inhibits thyroid cell proliferation by targeting the EGFR/MAPK and IRS2/PI3K signaling pathways”
https://doi.org/10.18632/oncotarget.28030
Review - “Genetic testing for homologous recombination repair (HRR) in metastatic castration-resistant prostate cancer (mCRPC): challenges and solutions” https...
2021-08-0406 min
OncotargetOncotarget: Biomarker Predicts Treatment Efficacy in Triple-Negative Breast CancerBiomarkers are any measurement in the body that can indicate disease, infection, or effects of the environment. These indicators are commonly used to reveal disease, but they can also be used to support personalized cancer therapy.
“In recent years, there has been an increased focus on personalized cancer therapy. One important aspect is the identification of key biomarkers that support a given treatment plan.”
Multiple biomarkers have been identified in breast cancers as helpful tools to guide targeted therapies, including the expression of HER2 and estrogen and progesterone receptors. In triple-negative breast cancer (TNBC), a number of distinct biomarkers have given ri...
2021-07-2805 min
OncotargetOncotarget: LAPAS1 is required for S phase progression and cell proliferationOncotarget published "A novel E2F1-regulated lncRNA, LAPAS1, is required for S phase progression and cell proliferation" which reported that long non-coding RNAs are major regulators of many cellular processes, including cell cycle progression and cell proliferation.
Inhibition of LAPAS1 expression increases the percentage of S phase cells, and its silencing in synchronized cells delays their progression through S phase.
In agreement with its suggested role in cell cycle progression, prolonged inhibition of LAPAS1 attenuates proliferation of human cancer cells.
Importantly, knockdown of SPNS2 rescues the effect of LAPAS1 silencing on cell cycle and cell proliferation.
Summarily, they identify...
2021-07-2602 min
OncotargetOncotarget: Metal Compounds Induce DNA Instability In Cancer CellsOncotarget’s cover paper this week (Volume 12, Issue 15) is entitled, "Terpyridine platinum compounds induce telomere dysfunction and chromosome instability in cancer cells."
About the Study:
Researchers from the National Institutes of Health, University Paris-Saclay, Kazusa DNA Research Institute, and the University of Edinburgh used a dual-Human Artificial Chromosome (HAC) assay to analyze the genomic activity of six telomere-targeting platinum compounds.
The dual-HAC assay was previously created by the researchers in this study to detect compounds that induce CIN through telomere dysfunction. This assay consists of two cell lines: one with telomeres, and one without. Disruption of the cell lines with te...
2021-07-2205 min
OncotargetTable of Contents: Oncotarget Volume 12, Issue #15Listen to summaries of the latest oncology-focused research published in this week’s issue of Oncotarget, Volume 12, Issue 15.
https://www.oncotarget.com/archive/v12/i15/
Cover Paper - “Terpyridine platinum compounds induce telomere dysfunction and chromosome instability in cancer cells”
https://doi.org/10.18632/oncotarget.28020
Research Paper - “RNA expression differences in prostate tumors and tumor-adjacent stroma between Black and White Americans” https://doi.org/10.18632/oncotarget.28024
Research Paper - “Next-generation multimodality of nutrigenomic cancer therapy: sulforaphane in combination with acetazolamide actively target bronchial carcinoid cancer in disabling the PI3K/Akt/mTOR survival pathway and inducing apoptosis”
https://doi.org/10.18632/oncotarget.28011
Research Paper...
2021-07-2108 min
OncotargetOncotarget: Targeted Treatment for Recurrent Ovarian CancerOncotarget published this trending research paper on May 1, 2018, entitled, "Treatment of ovarian cancer by targeting the tumor stem cell-associated carbohydrate antigen, Sialyl-Thomsen-nouveau" by researchers from the Massachusetts General Hospital, Boston, MA; Siamab Therapeutics, Inc., Newton, MA; Harvard Medical School, Boston, MA.
Abstract:
Recurrent ovarian cancer (OvCa) is thought to result in part from the inability to eliminate rare quiescent cancer stem cells (CSCs) that survive cytotoxic chemotherapy and drive tumor resurgence. The Sialyl-Thomsen-nouveau antigen (STn) is a carbohydrate moiety present on protein markers of CSCs in pancreatic, colon, and gastric malignancies. We have demonstrated that human OvCa cell lines contain...
2021-07-1605 min
OncotargetOncotarget: Expanding Research With TrendMDOncotarget has started a new venture to expand our reach and connect with other relevant platforms using TrendMD. The TrendMD widget has been applied at the bottom of all research papers on Oncotarget.com to serve recommended content to our readers, and readers on thousands of other high-traffic websites and scholarly platforms. Recommended content is based on the content currently being viewed, content that has been viewed in the past, and content other similar readers are viewing.
“[TrendMD’s] recommendation algorithms continuously optimize the placements of links to your content for the right audience while readers are actively looking for some...
2021-07-1503 min
OncotargetOncotarget: Esomeprazole and Tumor ControlThis week's cover paper of Oncotarget (Volume 12, Issue 14) is entitled, "Esomeprazole enhances the effect of ionizing radiation to improve tumor control," by researchers from Baylor College of Medicine, University of Texas MD Anderson Cancer Center, and Texas Children’s Hospital.
Abstract:
The resistance of cancer cells to radiation-based treatment is a major clinical challenge confounding standard of care in cancer. This problem is particularly notable in many solid tumors where cancer cells are only partially responsive to radiation therapy. Combination of radiation with radiosensitizers is able to enhance tumor cell killing. However, currently available radiosensitizers are associated with significant normal ti...
2021-07-0804 min
OncotargetTable of Contents: Oncotarget Volume 12, Issue #14Listen to short summaries of the latest oncology-focused research published in this week’s issue of Oncotarget, Volume 12, Issue 14.
https://www.oncotarget.com/archive/v12/i14/
Cover Paper - “Esomeprazole enhances the effect of ionizing radiation to improve tumor control” https://doi.org/10.18632/oncotarget.28008
Research Paper - “Mebendazole disrupts stromal desmoplasia and tumorigenesis in two models of pancreatic cancer”
https://doi.org/10.18632/oncotarget.28014
Research Paper - “MRI texture features from tumor core and margin in the prediction of response to neoadjuvant chemotherapy in patients with locally advanced breast cancer” https://doi.org/10.18632/oncotarget.28002
Research Paper - “The use of a uPAR-targeted pr...
2021-07-0708 min
OncotargetOncotarget: Breast cancer cells to ONC201 from anti-proliferative to apoptoticOncotarget published "TRAIL receptor agonists convert the response of breast cancer cells to ONC201 from anti-proliferative to apoptotic" which reported normal fibroblasts do not undergo apoptosis following rhTRAIL plus ONC201. In vivo, MDA-MB-361 tumor growth rate is significantly reduced following treatment with a combination of ONC201 and rhTRAIL as compared to control tumors.
Natural killer cells which use TRAIL to kill DR5-expressing cancer cells, exhibit greater cytotoxicity against ONC201-treated breast cancer cells compared to controls.
rhTRAIL also converts the response of cells from other tumor types to ONC201 from anti-proliferative to apoptotic.
A monoclonal DR5-agonistic antibody converts...
2021-07-0635 min
OncotargetOncotarget: ONC201 Induces Apoptosis in Breast CancerOncotarget published this trending research paper on October 20, 2020, entitled, "TRAIL receptor agonists convert the response of breast cancer cells to ONC201 from anti-proliferative to apoptotic" by researchers from Temple University, Philadelphia, PA; Fox Chase Cancer Center, Philadelphia, PA; Brown University, Providence, RI; Brown University and the Lifespan Health System, Providence, RI.
Abstract:
ONC201 was initially identified as an inducer of cell death through the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) pathway. The compound is currently being tested in patients with hematological malignancies and solid tumors, including those of the breast. We investigated strategies to convert the response of breast cancers...
2021-07-0206 min
OncotargetOncotarget: LAT1 - A Promising Anti-Cancer TargetThis week's cover paper of Oncotarget (Volume 12, Issue 13) is entitled, "Oncogenic transformation of NIH/3T3 cells by the overexpression of L-type amino acid transporter 1, a promising anti-cancer target," by researchers from Kindai University, Higashiosaka-Shi, Osaka, Japan; Tohoku University, Sendai-Shi, Miyagi, Japan; Tokyo University of Science, Noda-shi, Chiba, Japan; Hyogo University of Health Sciences, Kobe-Shi, Hyogo, Japan.
Abstract:
L-type amino acid transporter 1 (LAT1)/SLC7A5 is the first identified CD98 light chain disulfide linked to the CD98 heavy chain (CD98hc/SLC3A2). LAT1 transports large neutral amino acids, including leucine, which activates mTOR, and is highly expressed in human cancers...
2021-06-2505 min
OncotargetTable of Contents: Oncotarget Volume 12, Issue #13Listen to short summaries of the latest oncology-focused research published in this week’s issue of Oncotarget, Volume 12, Issue 13.
https://www.oncotarget.com/archive/v12/i13/
Cover Paper
“Oncogenic transformation of NIH/3T3 cells by the overexpression of L-type amino acid transporter 1, a promising anti-cancer target”
https://doi.org/10.18632/oncotarget.27981
News
“A new class of radiosensitizers for glioblastoma”
https://doi.org/10.18632/oncotarget.27970 (PDF Download)
Research Paper
“A platform for locoregional T-cell immunotherapy to control HNSCC recurrence following tumor resection”
https://doi.org/10.18632/oncotarget.27982
Research Paper
“Human papilloma virus circulating tumor DNA assay predicts treatment response in recurrent/metastatic head and neck squamous ce...
2021-06-2309 min
OncotargetOncotarget: CRISPR Used in Triple Negative Breast Cancer ResearchIn this week's cover paper of Oncotarget (Volume 12, Issue 12), entitled, "Frame-shift mediated reduction of gain-of-function p53 R273H and deletion of the R273H C-terminus in breast cancer cells result in replication-stress sensitivity," researchers used the CRISPR-Cas9 tool to analyze a p53 mutation in triple-negative breast cancer.
The researchers from the City University of New York, Columbia University, and Weill Cornell Medical College wrote that both the C-terminal domain (CTD) and oligomerization domain (OD) of mtp53 R273H proteins are intact, and it is not clear if these regions are responsible for chromatin-based DNA replication activities. To examine the ability...
2021-06-1007 min
OncotargetTable of Contents: Oncotarget Volume 12, Issue #12Listen to the latest oncology-focused research published in this week’s issue of Oncotarget, Volume 12, Issue 12.
The full issue of Oncotarget: https://www.oncotarget.com/archive/v12/i12/
COVER PAPER:
“Frame-shift mediated reduction of gain-of-function p53 R273H and deletion of the R273H C-terminus in breast cancer cells result in replication-stress sensitivity”
https://doi.org/10.18632/oncotarget.27975
NEWS:
“LY6 gene family presents a novel class of potential biomarkers associated with overall survival outcome of pancreatic ductal adenocarcinoma”
https://doi.org/10.18632/oncotarget.27968 (PDF Download)
EDITORIAL:
“Neoantigen evolution in head and neck cancer progression: Where do we go from here?”
https://doi.org/10.18632/o...
2021-06-0906 min
OncotargetOncotarget: Novel Urine Protein Biomarkers In Bladder CancerOncotarget published this trending research paper on April 13, 2021, entitled, "Urine protein biomarkers of bladder cancer arising from 16-plex antibody-based screens" conducted by researchers from the University of Houston and UT Southwestern Medical Center.
Bladder cancer is four times more common among men than women, and it is the sixth most common cancer diagnosis in the United States. However, researchers have found that cystoscopy—the primary method physicians use to diagnose patients with bladder cancer—is relatively invasive, expensive, and has the potential to cause urinary tract infections.
“In contrast, urine is a noninvasive and readily available biological fluid that can be use...
2021-06-0404 min
OncotargetOncotarget: Blood-Based Biomarker in SCCAIn this week's cover paper of Oncotarget (Volume 12, Issue 11) entitled, "CEA as a blood-based biomarker in anal cancer," researchers from The University of Texas – MD Anderson Cancer Center, Terasaki Foundation of Biomedical Sciences, and Vanderbilt Ingram Cancer Center conducted a retrospective, single-institution study to determine the correlation between carcinoembryonic antigen (CEA) levels (a commonly employed assay for patients with colorectal adenocarcinoma) and biopsy-proven Squamous cell carcinoma of the anal canal (SCCA).
The researchers retrospectively analyzed 219 patients who were treated at The University of Texas – MD Anderson Cancer Center between 2013 and 2020. The team collected demographic data, clinical history, and CEA levels, incl...
2021-05-2705 min
OncotargetTable of Contents: Oncotarget Volume 12, Issue #11Listen to the latest oncology-focused research published in this week’s issue of Oncotarget, Volume 12, Issue 11.
View the complete issue: https://www.oncotarget.com/archive/v12/i11/
COVER PAPER:
“CEA as a blood-based biomarker in anal cancer”
https://doi.org/10.18632/oncotarget.27959
NEWS:
“FGFR1, a novel biomarker for metastatic castration-resistant prostate cancer?”
https://doi.org/10.18632/oncotarget.27957 (PDF Download)
EDITORIAL:
“Advances in innovative exosome-technology for real time monitoring of viable drugs in clinical translation, prognosis and treatment response”
https://doi.org/10.18632/oncotarget.27927 (PDF Download)
EDITORIAL:
“Drug-development, dose-selection, rational combinations from bench-to-bedside: are there any lessons worth revisiting?” https://doi.org/10.18632/oncotarget.27931 (PDF Download)
RESEARCH...
2021-05-2608 min
OncotargetOncotarget Launches Special Collection on Skin CancerSkin cancer is a highly preventable cancer (in non-hereditary cases), due to a major risk factor being prolonged exposure to ultraviolet (UV) radiation. However, skin cancer is the most commonly diagnosed cancer in the United States. By the age of 70, one in five Americans are predicted to be diagnosed with skin cancer.
There are three types of cells that are usually involved in skin cancer: basal cells, squamous cells, and melanocytes (or pigment producing cells). The type of skin cell affected by cancer is what classifies the difference between basal cell carcinoma, squamous cell carcinoma, and melanoma.
Basal cell carcinoma...
2021-05-2102 min
OncotargetOncotarget: Inhibitory Effects of Tomivosertib in Acute Myeloid LeukemiaIn the cover paper of this week's issue of Oncotarget (Volume 12, Issue 10), titled, "Inhibitory effects of Tomivosertib in acute myeloid leukemia," researchers based out of Chicago, Illinois, U.S., from Northwestern University’s Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, and Jesse Brown Veterans Affairs Medical Center conducted a new study to assess the efficacy of Tomivosertib to regulate the eIF4E binding protein in AML.
In this study, the researchers purchased Tomivosertib (and Venetoclax) from TargetMol. They cultured AML cell lines, used clonogenic leukemic progenitor assays in methylcellulose, cell viability assays, cell lysis and im...
2021-05-1306 min
OncotargetTable of Contents: Oncotarget Volume 12, Issue #10Listen to the latest oncology-focused research published in this week’s issue of Oncotarget, Volume 12, Issue 10.
View the complete issue: https://www.oncotarget.com/archive/v12/i10/
COVER PAPER:
“Inhibitory effects of Tomivosertib in acute myeloid leukemia” https://doi.org/10.18632/oncotarget.27952
EDITORIAL:
“Raman spectroscopy determination of the mineral characteristics of microcalcifications in breast cancer, a way towards an improved screening approach” https://doi.org/10.18632/oncotarget.27912 (PDF Download)
EDITORIAL:
“Reactive oxygen species in leukemias: maintaining cancer cell proliferation via redox signaling and changing metabolic homeostasis” https://doi.org/10.18632/oncotarget.27913 (PDF Download)
RESEARCH PAPER:
“Genome wide DNA methylation landscape reveals glioblastoma’s influence on epige...
2021-05-1106 min
OncotargetOncotarget: Evaluating Role of IGF/CTP Composite Score in Sorafenib TreatmentOncotarget published this trending research paper on April 13, 2021, entitled, “Insulin-like growth factor 1/Child-Turcotte-Pugh composite score as a predictor of treatment outcomes in patients with advanced hepatocellular carcinoma treated with sorafenib,” by researchers from the University of Texas MD Anderson Cancer Center, Massachusetts General Hospital, and Harvard Medical School.
The majority of circulating insulin–like growth factor (IGF) is synthesized and secreted by the liver, and levels of IGF dramatically decrease in chronic liver disease and HCC. IGF can be a helpful tool to determine the prognosis of patients with advanced HCC while undergoing treatment with sorafenib. Researchers also use the Child...
2021-05-0805 min
OncotargetOncotarget: A New Class of Radiosensitizers for GlioblastomaIn the cover paper of this week's issue of Oncotarget (Volume 12, Issue 9), titled, "Creation of a new class of radiosensitizers for glioblastoma based on the mibefradil pharmacophore," researchers conducted a study to create mibefradil analogs as superior radiosensitizers for glioblastomas.
In the current study, based on their previous findings, the researchers from Yale University used structure activity relationship analysis and EJ-DR assays to create, synthesize, and profile a series of 140 mibefradil analogs. Their goal was to develop superior mibefradil analogues, with reduced off-target effects and improved potency.
After successfully reducing the known off-target liabilities of mibefradil, the team selected the...
2021-04-2905 min
OncotargetTable of Contents: Oncotarget Volume 12, Issue #9Listen to the latest oncology-focused research published in this week’s issue of Oncotarget, Volume 12, Issue 9.
View the complete issue: https://www.oncotarget.com/archive/v12/i9/
Oncotarget Volume 12, Issue 9 features:
COVER PAPER:
“Creation of a new class of radiosensitizers for glioblastoma based on the mibefradil pharmacophore” https://doi.org/10.18632/oncotarget.27933
EDITORIAL:
“Is there a role for CDK 4/6 inhibitors in breast cancer brain metastases?” https://doi.org/10.18632/oncotarget.27904 (PDF Download)
EDITORIAL:
“Epigenetic effects of pharmacologic ascorbate” https://doi.org/10.18632/oncotarget.27911 (PDF Download)
RESEARCH PAPER:
“Activation of plasmacytoid dendritic cells promotes AML-cell fratricide” https://doi.org/10.18632/oncotarget.27949
RESEARCH PAPER:
“Piperlongumine promotes death of retinoblast...
2021-04-2807 min
OncotargetOncotarget: Midostaurin Drug Sensitivity Ex Vivo in Acute Myeloid LeukemiaOncotarget published this trending paper on July 21, 2020, entitled, “Genomic markers of midostaurin drug sensitivity in FLT3 mutated and FLT3 wild-type acute myeloid leukemia patients,” by researchers from Knight Cancer Institute, Oregon Health and Science University; Division of Hematology and Medical Oncology, Oregon Health and Science University; Howard Hughes Medical Institute; Department of Cell, Developmental, and Cancer Biology, Oregon Health and Science University.
The researchers conducted a study to identify features that may predict response to midostaurin in FLT3 mutant and wild-type samples. They performed an ex vivo drug sensitivity screen on primary and relapsed AML samples, with corresponding targeted sequencing and...
2021-04-2705 min
OncotargetOncotarget: A New Potential Network of Biomarkers Useful Across SarcomasIn the cover paper of this week's issue of Oncotarget (Volume 12, Issue 8), titled, "Prognostic and therapeutic value of the Hippo pathway, RABL6A, and p53-MDM2 axes in sarcomas," researchers examined five potential biomarkers across 18 different histologic subtypes of sarcoma in 163 tissue samples. Immunohistochemical staining, statistical analysis, and correlation-based network analysis revealed promising results.
Researchers from the University of Iowa, University of Alabama at Birmingham, and the Mayo Clinic, report the need for additional prognostic and therapeutic biomarkers to predict clinical behavior across different histological types of sarcoma.
“Although the French (FNCLCC) and NCI grading schemes have been adopted for ma...
2021-04-1508 min
OncotargetTable of Contents: Oncotarget Volume 12, Issue #8Listen to short summaries of the latest oncology-focused research published in this week's issue of Oncotarget. https://www.oncotarget.com/archive/v12/i8/
Oncotarget Volume 12, Issue 8 features:
COVER PAPER:
“Prognostic and therapeutic value of the Hippo pathway, RABL6A, and p53-MDM2 axes in sarcomas” https://doi.org/10.18632/oncotarget.27928
NEWS:
“Immunotherapy and fatigue: what we know and what we don’t know” https://doi.org/10.18632/oncotarget.27946 (PDF Download)
EDITORIAL:
“Drug exposure: still relevant after all these years” https://doi.org/10.18632/oncotarget.27899 (PDF Download)
EDITORIAL:
“Up to your NEK2 in CIN” https://doi.org/10.18632/oncotarget.27918 (PDF Download)
RESEARCH PAPER:
“Analytic validation and clinical utiliza...
2021-04-1409 min
OncotargetOncotarget: First Blood Test for Early Melanoma Detection (A 2018 Study)In this top-performing paper published in Oncotarget on July 17, 2018, entitled, “A diagnostic autoantibody signature for primary cutaneous melanoma,” Australian researchers developed the first blood test to detect melanoma in early stages.
The researchers from Australia’s Edith Cowan University, Hollywood Private Hospital, Level 1 Melanoma, St. John of God Hospital, Dermatology Specialist Group, Skin Check WA, and The University of Western Australia collected blood sera (plural of serum, which contains exogenous substances in the blood, such as electrolytes, antibodies, autoantibodies, antigens, and hormones) from a total of 245 primary melanoma patients and healthy volunteers. The sera were screened against a high-throughput microarray profil...
2021-04-0705 min
OncotargetOncotarget: Caloric Restriction and Aging Delay in Budding YeastIn Oncotarget Volume 12, Issue 7 cover paper, titled, "Caloric restriction creates a metabolic pattern of chronological aging delay that in budding yeast differs from the metabolic design established by two other geroprotectors," the researchers conducted a study which compared the metabolic effects of three geroprotectors in budding yeast: calorie restriction, the tor1Δ mutation, and lithocholic acid.
In this study, the researchers from the Department of Biology at Concordia University in Montreal, Quebec, used chronologically aging Saccharomyces cerevisiae—a common budding yeast found in baking, winemaking, and beer brewing. S. cerevisiae is a fungus useful for measuring the mechanisms of aging. The res...
2021-04-0206 min
OncotargetOncotarget: Participating in the AACR Annual MeetingThe American Association for Cancer Research (AACR) organizes an annual meeting program covering some of the most recent discoveries in cancer research. The conference aims to highlight work from the best minds in research and medicine from institutions all over the world. Oncotarget, exhibited by its publisher Impact Journals, will be participating virtually at the AACR Annual Meeting this year.
Visit the Oncotarget website: www.oncotarget.com
Visit the Impact Journals website: www.impactjournals.com
As of June 2020, Scopus released their latest 2019 Journal Rankings on Oncology. Oncotarget is among their highest rated (Q1) journals and ranked number one in total...
2021-04-0203 min
OncotargetTable of Contents: Oncotarget Volume 12, Issue #7Listen to short summaries of the latest oncology-focused research published in this week's issue of Oncotarget. https://www.oncotarget.com/archive/v12/i7/
Oncotarget Volume 12, Issue 7 features:
COVER PAPER:
"Caloric restriction creates a metabolic pattern of chronological aging delay that in budding yeast differs from the metabolic design established by two other geroprotectors"
https://doi.org/10.18632/oncotarget.27926
EDITORIAL:
"The long road to TRAIL therapy: a TRAILshort detour"
https://doi.org/10.18632/oncotarget.27902
RESEARCH PERSPECTIVE:
"The role of immune surveillance in malignant transformation of benign salivary gland tumors"
https://doi.org/10.18632/oncotarget.27900
RESEARCH PAPER:
"Differential expression of Vitamin D binding protein in...
2021-04-0210 min
OncotargetOncotarget: Quantitative Proteome Profiling Stratifies Fibroepithelial Lesions Of The BreastOncotarget published "Quantitative proteome profiling stratifies fibroepithelial lesions of the breast" which reported that the current grading system remains unreliable in differentiating these tumors due to histological heterogeneity and lack of appropriate markers to monitor the sudden and unpredictable malignant transformation of PTs.
The high- throughput quantitative proteomic analysis suggested that FAD and PTs form distinct clusters away from borderline and malignant though there exist marked differences between them.
Interestingly, over-expression of extracellular matrices related proteins and epithelial-mesenchymal transition markers in borderline PTs led these authors to hypothesize a model of deposition and degradation leading to ECM remodeling and EMT...
2021-03-1804 min
OncotargetOncotarget: Neoantigen Evolution in Head and Neck TumorsIn the cover paper of this week's issue of Oncotarget, titled: "Genomic and neoantigen evolution from primary tumor to first metastases in head and neck squamous cell carcinoma," the aim of the researchers in this exploratory study was to characterize the genomic and neoantigen changes in 23 paired primary and recurrent HNSCC tumors.
Of the 23 patients in this study, 17 were male and 14 were tobacco smokers. The distribution of primary tumor location was nine in the oral cavity, seven in the oropharynx, six in the larynx, and one in the hypopharynx. The researchers note that all seven patients with an oropharyngeal primary...
2021-03-1707 min
OncotargetTable of Contents: Oncotarget Volume 12, Issue #6Listen to short summaries of the latest oncology-focused research literature published in this week's issue of Oncotarget.
https://www.oncotarget.com/archive/v12/i6/
Oncotarget Volume 12, Issue 6 features:
COVER PAPER:
"Genomic and neoantigen evolution from primary tumor to first metastases in head and neck squamous cell carcinoma."
Institutions: Washington University in St. Louis, Columbia University, St. Louis Children’s Hospital, Siteman Cancer Center
Quote: “We characterized genomic and neoantigen changes between 23 paired primary and recurrent HNSCC tumors. Twenty-three biopsies from patients originally diagnosed with locally advanced disease were identified from the Washington University tumor bank.”
doi.org/10.18632/oncotarget.27907
EDITORIAL:
"Innovating and ex...
2021-03-1604 min
OncotargetOncotarget: Hepatocellular Carcinoma in The Andes MountainsIn a trending paper published by Oncotarget on March 2, 2021, researchers conducted a study to better understand why young Andean people are disproportionately affected by hepatocellular carcinoma (HCC) than others around the world.
Hepatocellular carcinoma (HCC) is one of the most heterogeneous forms of cancer, and affects older patients commonly after they have had prolonged liver disease. However, among Andean people, half of the total patients who develop HCC are adolescents and young adults. Researchers—from Sorbonne Université, Institut Pasteur, Université de Rennes, and Université de Toulouse in France, and the Instituto Nacional de Enfermedades Neoplásicas in Peru—conducted a study to...
2021-03-1205 min
OncotargetOncotarget: Can Precision Oncology Improve Patient Survival AND Cut Costs?Oncotarget published this top-performing paper in 2018, when researchers compared the overall survival, average total healthcare costs, and resource utilization among patients with advanced cancers who received either standard care or precision, targeted oncology.
The researchers, from Intermountain Healthcare facilities (located in Utah and California, U.S.) and California’s Stanford University School of Medicine, conducted a well-read study published in 2018, titled: “Precision oncology in advanced cancer patients improves overall survival with lower weekly healthcare costs.” This paper currently presents with an Altmetric attention score of 484.
Read about the study: https://www.oncotarget.com/article/24384/text/
Top Oncotarget publications rated by Altmet...
2021-03-1005 min
OncotargetOncotarget: The First Study on CABYR Isoforms in Colorectal CancerIn the cover paper of this week's issue of Oncotarget, titled: "The cancer testis antigens CABYR-a/b and CABYR-c are expressed in a subset of colorectal cancers and hold promise as targets for specific immunotherapy," researchers evaluate CABYR isoforms a/b and c mRNA expression in colorectal cancer in hopes of determining whether or not these proteins may be promising vaccine targets.
Read the full study here: https://doi.org/10.18632/oncotarget.27897
Oncotarget Volume 12, Issue 5: https://www.oncotarget.com/archive/v12/i5/
About Oncotarget:
Oncotarget is a bi-weekly, peer-reviewed, open access biomedical journal covering research on all aspects of oncology.
To...
2021-03-0506 min
OncotargetTable of Contents: Oncotarget Volume 12, Issue #5Listen to short summaries of the latest oncology-focused research literature published in this week's issue of Oncotarget Volume 12, Issue 5.
Click here for the complete issue: https://www.oncotarget.com/archive/v12/i5/
Oncotarget Volume 12, Issue 5 features:
Cover Paper: "The cancer testis antigens CABYR-a/b and CABYR-c are expressed in a subset of colorectal cancers and hold promise as targets for specific immunotherapy." https://doi.org/10.18632/oncotarget.27897
Research Perspective: "Tumor mutational burden as a predictor of immunotherapy response in breast cancer." https://doi.org/10.18632/oncotarget.27877
Research Paper: "STAT3 induces the expression of GLI1 in chronic lymphocytic leukemia cells." https://doi.org/10.18632...
2021-03-0308 minOncotargetOncotarget Podcast Episodes: The Latest in Oncology-Focused ResearchHundreds of scientific studies, reviews, and analyses are being published from around the world at any given time. This can make reading the latest research literature a time consuming task—depending, of course, on the quantity of papers one hopes to consume. As a tool to help alleviate this important undertaking, many researchers have taken to listening to one of the top open-access podcasts of 2020 and 2021: The Oncotarget Podcast.
After a paper is published, it is added to an enhanced post-publication service provided by Oncotarget, in an effort to help authors reach a wider audience. This podcast series is another wa...
2021-02-2402 min
OncotargetOncotarget: Combination Therapy TA99 ICB Reduced The Lung Tumor BurdenThe cover for issue 2 of Oncotarget features Figure 4, "Combination therapy TA99/ICB reduced the lung tumor burden in the B16 model of metastases," published in "Improved therapeutic efficacy of unmodified anti-tumor antibodies by immune checkpoint blockade and kinase targeted therapy in mouse models of melanoma" by Pérez-Lorenzo, et al. which reported that here, the authors showed that removing immune suppression and enhancing stimulatory signals increased the anti-tumor activity of unmodified TA99 antibodies with a significant reduction of growth of solid tumors and lung metastases in mouse models of melanoma.
Immune checkpoint blockade enhanced the efficacy of TA99, which was a...
2021-01-2104 min
OncotargetOncotarget - CART Tree Analysis For Overall Survival In IMDC Intermediate Risk GroupThe cover for issue 49 of Oncotarget features Figure 4, "CART-Tree analysis for overall survival in IMDC intermediate risk group," by Guida, et al.recently published in "Identification of international metastatic renal cell carcinoma database consortium (IMDC) intermediate-risk subgroups in patients with metastatic clear-cell renal cell carcinoma" which reported that as these patients have different prognosis, the aim of this study is to better characterize IR patients in order to better tailor the treatment.
A multivariable Cox model with backward selection procedure and a Classification and Regression Tree analysis were performed to identify which prognostic factors were associated to OS in IR...
2020-12-1003 min
OncotargetOncotarget: HIV +/- patients with lymphoma as a predictor of outcome & tumor proliferationThe cover for issue 45 of Oncotarget features Figure 3, "Representative images of whole tumor volume segmentation of the co-registered T1 post-contrast sequence and apparent diffusion coefficient (ADC) map, yielding the corresponding ADC histogram distribution utilized for data analysis," recently published in “Diffusion-weighted MR imaging histogram analysis in HIV positive and negative patients with primary central nervous system lymphoma as a predictor of outcome and tumor proliferation” by Khan, et al.
This authors reported that the aim of this study is to investigate the correlation between ADC parameters, Ki-67 expression, overall survival and progression free survival in PCNSL.
Selection criteria yielded 90 patients, 23 pati...
2020-11-1604 min
OncotargetOncotarget Podcast: IGF2 expression in breast cancer tumors and in breast cancer cellsThe cover for issue 44 of Oncotarget features Figure 1, "Schematic diagram of the human IGF2 gene structure," by Radhakrishnan, et al. recently published in "Methylation of a newly identified region of the INS-IGF2 gene determines IGF2 expression in breast cancer tumors and in breast cancer cells" which reported that these authors previously demonstrated that IGF2 protein levels are higher in BC tissues from African American women than in Caucasian women.
They also showed that high IGF2 protein levels are expressed in normal breast tissues of African American women while little or no IGF2 was detected in tissues from Caucasian women.
Thus...
2020-11-0603 min
OncotargetOncotarget: A chance for targeting cancer stem cells in human non-small cell lung cancer?Oncotarget recently published "CD44+/EPCAM+ cells detect a subpopulation of ALDHhigh cells in human non-small cell lung cancer: A chance for targeting cancer stem cells?" which reported that a comparison between ALDH high cells and CD44 cells have been previously described with no significant correlation.
This cross-sectional study analyzed the expression of ALDHhigh/low cells and the positivity for CD44 and epithelium cell adhesion molecule antigens in surgical lung cancer tissues.
There was a highly positive correlation between the expressions of ALDHhigh and CD44 /EPCAM cells, with a Pearson’s correlation coefficient equal to 0.69, and Spearman’s correlation coefficient equal to 0...
2020-11-0206 min
OncotargetOncotarget - Generation Of Parametric And Texture Maps From Radiofrequency DataThe cover for Issue 42 of Oncotarget features Figure 4, "Generation of parametric and texture maps from radiofrequency data," recently published in "Quantitative ultrasound radiomics using texture derivatives in prediction of treatment response to neo-adjuvant chemotherapy for locally advanced breast cancer" by Dasgupta, et al. which reported that to investigate quantitative ultrasound based higher-order texture derivatives in predicting the response to neoadjuvant chemotherapy in patients with locally advanced breast cancer.
Three machine learning algorithms based on linear discriminant, k-nearest-neighbors, and support vector machine were used for developing radiomic models of response prediction.
The most helpful features in separating the two response groups...
2020-10-2204 min
OncotargetOncotarget - Efavirenz Induces DNA Damage Response Pathway In Lung CancerThe cover for Issue 41 of Oncotarget features Figure 7, "IPA ATM-signaling pathway in (A) EFV treated MRC-5 and (B) A549 cells," recently published in "Efavirenz induces DNA damage response pathway in lung cancer" by Marima, et al. which reported that the cell-cycle related genes are potential gene targets in understanding the effects of efavirenz in lung cancer.
The present study aimed at investigating the expression changes of cell-cycle related genes in response to EFV drug treatment in human non-small cell lung carcinoma and normal lung fibroblast cells.
The loss in nuclear integrity in response to EFV was detected by 4′, 6-diamidino-2-phenylindole st...
2020-10-1604 min
OncotargetOncotarget - Exosomes Secreted Under Hypoxia Enhance Stemness In Ewing's SarcomaThe cover for issue 40 of Oncotarget features Figure 5, "miR-210 silences the proapoptosis member CASP8AP2," by Kling, et al. which reported that hypoxic Ewing's sarcoma cells release exosomes that promote sphere formation, a stem-like phenotype, in EWS cells by enhancing survival.
Analysis of the hypoxic exosomal miRNA cargo identified a HIF-1α regulated miRNA, miR-210, as a potential mediator of sphere formation in cells exposed to hypoxic exosomes.
The knockdown of HIF-1α in hypoxic EWS cells led to decreased exosomal miR-210 levels and reduced the capacity of hypoxic exosomes to form spheres.
Inhibition of miR-210 in hypoxic spheres attenuated sphere formation an...
2020-10-0804 min
OncotargetOncotarget - NRXN1 As A Novel Potential Target For Small Cell Lung CancerThe cover for issue 39 of Oncotarget features Figure 4, "Apoptosis assay of NRXN1-targeted ADC at IC50 dose calculated by growth inhibition curves," by Yotsumoto, et al. which reported that the authors identified transmembrane proteins overexpressed specifically in SCLC with little or no expression in normal tissues and decided to focus on the cell adhesion molecule neurexin-1.
The cell surface overexpression of NRXN1 was confirmed using flow cytometry in SCLC cell lines.
The combination of a primary anti-NRXN1 monoclonal antibody and a secondary ADC exhibited anti-tumor activity in SCLC cell lines.
Moreover, the knockout of NRXN1 in SHP77 cells resulted in...
2020-09-3003 min
OncotargetOncotarget - A Comprehensive Analysis Of Clinical Trials In Pancreatic CancerThe cover for issue 38 of Oncotarget features Figure 3, "Summary of the time and cost for drug development (modified from DiMasi et al [2016]," by Katayama, et al. which reported that Pancreatic cancer is the most aggressive common cancer and is desperately in need of novel therapies.
In this study, the Oncotarget authors perform the first comprehensive analysis of the current clinical trial landscape in pancreatic cancer to better understand the pipeline of new therapies.
Studies were curated and categorized according to the phase of the study, the clinical stage of the study population, type of intervention under investigation, and biologic mechanism...
2020-09-2303 min
OncotargetOncotarget - ATM Inhibition Overcomes Resistance To Histone Deacetylase InhibitorThe cover for issue 37 of Oncotarget features Figure 7, "The combination of romidepsin and KU60019 is synergistic in a xenograft model of MCL," by Scotto, et al. which reported that the antiproliferative effect induced by histone deactylase inhibitors is associated with the up-regulated expression of the cyclin-dependent kinase inhibitor p21. Paradoxically, the increased expression of p21 correlates with a reduced cell killing to the drug.
HDAC inhibitors appear to activate p21 expression via ataxia telangiectasia mutated activity.
The Oncotarget authors explored the potential synergistic interaction of the ATM inhibitor with romidepsin, given the potential complementary impact around p21. A synergistic cytotoxic...
2020-09-1604 min